Pfizer's Abrysvo becomes first maternal RSV shot to protect newborns
Fierce Pharma
AUGUST 22, 2023
Already with an approval in hand for older adults, Pfizer’s Abrysvo has become the first vaccine for pregnant women to protect their newborns against respiratory syncytial virus (RSV). The FDA has signed off on Abrysvo for women who have been pregnant for 32 to 36 weeks.
171 
Let's personalize your content